Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile ROCKVILLE, MD--(Marketwire - February 2, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced that it has begun delivery of 20,000 doses of its human monoclonal antibody drug...